P. Landis

发表

Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer.

Mufaddal Mamawala, Bruce J Trock, H Ballentine Carter, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience

Alan W Partin, Bruce J Trock, H Ballentine Carter, 2011 .

Today men with prostate cancer have larger prostates.

E. Metter, E. Metter, P. Walsh, 2000, Urology.

Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy.

E. Metter, E. Platz, H. Carter, 2006, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging.

E. Metter, D. Chan, H. Carter, 2001, Urology.

Multiparametric magnetic resonance imaging findings in men with low‐risk prostate cancer followed using active surveillance

A. Partin, K. Macura, D. Bonekamp, 2013, BJU international.

Calcium intake and prostate cancer risk in a long-term aging study: the Baltimore Longitudinal Study of Aging.

E. Metter, S. Berndt, E. Platz, 2002, Urology.

Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program.

A. Partin, L. Sokoll, J. Epstein, 2010, The Journal of urology.

Metabolic factors associated with benign prostatic hyperplasia.

L. Ferrucci, E. Metter, A. Partin, 2006, The Journal of clinical endocrinology and metabolism.

Risk stratification of men choosing surveillance for low risk prostate cancer.

B. Trock, J. Epstein, Kenneth S. Tseng, 2009, The Journal of urology.

Serum prostate‐specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density

A. Partin, E. Platz, J. Epstein, 2014, BJU international.

Utility of multiparametric magnetic resonance imaging in the risk stratification of men with Grade Group 1 prostate cancer on active surveillance

A. Partin, K. Macura, J. Epstein, 2020, BJU international.

PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml.

E. Metter, H. Carter, P. Landis, 2002, Urology.

Risk stratification of men choosing surveillance for low risk prostate cancer.

B. Trock, J. Epstein, Kenneth S. Tseng, 2009, The Journal of urology.

Predictors of Adverse Pathology in Men Undergoing Radical Prostatectomy Following Initial Active Surveillance.

B. Trock, J. Epstein, H. Carter, 2014, Urology.

Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis.

J. Epstein, Misop Han, H. Carter, 2013, The Journal of urology.

Nonsteroidal Anti-inflammatory Drugs and Risk of Prostate Cancer in the Baltimore Longitudinal Study of Aging

E. Metter, E. Platz, A. D. De Marzo, 2005, Cancer Epidemiology Biomarkers & Prevention.

Effect of treatment with 5‐α reductase inhibitors on progression in monitored men with favourable‐risk prostate cancer

B. Trock, P. Walsh, P. Pierorazio, 2012, BJU international.

Targeted antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy during active surveillance: Effect on hospitalization.

Misop Han, H. Carter, P. Landis, 2018, Urologic oncology.

Fluoroquinolone resistance in the rectal carriage of men in an active surveillance cohort: longitudinal analysis.

Mark W. Ball, B. Trock, E. Schaeffer, 2015, The Journal of urology.

Comparison of Biochemical Recurrence‐Free Survival after Radical Prostatectomy Triggered by Grade Reclassification during Active Surveillance and in Men Newly Diagnosed with Similar Grade Disease

J. Epstein, M. Mamawala, P. Landis, 2017, The Journal of urology.

Repeat prostate biopsies predict location of index cancer in an active surveillance cohort

A. Partin, J. Epstein, F. Brimo, 2011, BJU international.

Imaging, Diagnosis, Prognosis Pro–Prostate-Specific Antigen Measurements in Serum and Tissue Are Associated with Treatment Necessity among Men Enrolled in Expectant Management for Prostate Cancer

A. Partin, L. Sokoll, J. Epstein, 2009 .

Expectant Management of Prostate Cancer with Curative Intent

P. Walsh, J. Epstein, H. Carter, 2001, European Urology.

Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance.

K. Fujita, C. Pavlovich, P. Landis, 2009, The Journal of urology.

Relationship between changes in prostate-specific antigen and the percent of prostatic epithelium in men with benign prostatic hyperplasia.

J. Cadeddu, A. Partin, J. Epstein, 1995, Urology.

Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. Tosoian JJ, Mamawala M, Epstein JI, Landis P, Wolf S, Trock BJ, Carter HB.J Clin Oncol. 2015 Oct 20;33(30):3379-85. [Epub 2015 Aug 31]. doi: 10.1200/JCO.2015.62.5764.

J. Epstein, H. Carter, M. Mamawala, 2017, Urologic oncology.

S. Freedland, H. Carter, M. Haffner, 2005, Urology.

Can a baseline prostate specific antigen level identify men who will have lower urinary tract symptoms later in life?

E. Metter, H. Carter, J. Parsons, 2005, The Journal of urology.

Effect of intra‐observer variation in prostate volume measurement on prostate‐specific antigen density calculations among prostate cancer active surveillance participants

Alan W Partin, H Ballentine Carter, A. Partin, 2011, BJU international.

Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases.

A. Partin, P. Walsh, J. Epstein, 1994, Urology.

Mixed-effects regression models for studying the natural history of prostate disease.

H. Carter, C. Morrell, J. Pearson, 1994, Statistics in medicine.

Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer.

E. Metter, H. Carter, M. Blackman, 2000, The Journal of clinical endocrinology and metabolism.

Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging.

E. Metter, E. Platz, S. Rohrmann, 2004, Urology.

Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?

A. Partin, J. Epstein, H. Carter, 2003, The Journal of urology.

Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.

Anna Kettermann, Alan W Partin, H Ballentine Carter, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.

L. Ferrucci, E. Metter, B. Trock, 2006, Journal of the National Cancer Institute.

Delayed versus immediate surgical intervention and prostate cancer outcome.

B. Trock, J. Epstein, H. Carter, 2006, Journal of the National Cancer Institute.

Expectant management of nonpalpable prostate cancer with curative intent: preliminary results.

P. Walsh, J. Epstein, H. Carter, 2002, The Journal of urology.

Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort.

K. Macura, J. Epstein, J. Tosoian, 2020, European urology.

Reclassification rates are higher among African American men than Caucasians on active surveillance.

B. Trock, E. Schaeffer, A. Ross, 2015, Urology.

Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance.

B. Trock, A. Partin, P. Walsh, 2013, The Journal of urology.

Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.

B. Trock, A. Partin, L. Sokoll, 2012, The Journal of urology.

Low prostate-specific antigen and no Gleason score upgrade despite more extensive cancer during active surveillance predicts insignificant prostate cancer at radical prostatectomy.

J. Epstein, H. Carter, A. Amin, 2012, Urology.

The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Active Surveillance.

K. Macura, J. Epstein, J. Tosoian, 2017, European urology.

Risk prediction tool for grade re‐classification in men with favourable‐risk prostate cancer on active surveillance

K. Pienta, B. Trock, J. Epstein, 2017, BJU international.

Pro–Prostate-Specific Antigen Measurements in Serum and Tissue Are Associated with Treatment Necessity among Men Enrolled in Expectant Management for Prostate Cancer

A. Partin, L. Sokoll, J. Epstein, 2009, Clinical Cancer Research.

Prediagnostic plasma vitamin C levels and the subsequent risk of prostate cancer.

E. Metter, S. Berndt, E. Platz, 2005, Nutrition.

Applied nutritional investigation Prediagnostic plasma vitamin C levels and the subsequent risk of prostate cancer

E. Metter, S. Berndt, E. Platz, 2005 .

Obesity does not adversely affect health-related quality-of-life outcomes after anatomic retropubic radical prostatectomy.

S. Freedland, H. Carter, M. Haffner, 2005, Urology.

Age-associated changes in blood pressure in a longitudinal study of healthy men and women.

J. Fleg, C. Morrell, J. Pearson, 1997, The journals of gerontology. Series A, Biological sciences and medical sciences.

Serum Testosterone and the Risk of Prostate Cancer: Potential Implications for Testosterone Therapy

E. Metter, E. Platz, H. Carter, 2005, Cancer Epidemiology Biomarkers & Prevention.

Magnetic resonance-invisible versus magnetic resonance-visible prostate cancer in active surveillance: a preliminary report on disease outcomes.

Katarzyna J Macura, Bruce J Trock, H Ballentine Carter, 2015, Urology.

1344: Metabolic Factors Associated with Benign Prostatic Hyperplasia: The Baltimore Longitudinal Study of Aging

L. Ferrucci, E. Metter, A. Partin, 2006 .

Prostate-specific antigen testing of older men.

E. Metter, L. Fleisher, H. Carter, 1999, Journal of the National Cancer Institute.

Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer.

B. Trock, J. Epstein, H. Carter, 2014, The Journal of urology.

Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging.

E. Metter, D. Chan, A. Partin, 2002, The Journal of urology.

Association of energy intake with prostate cancer in a long-term aging study: Baltimore Longitudinal Study of Aging (United States).

E. Metter, E. Platz, H. Carter, 2003, Urology.

ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program.

A. Partin, L. Sokoll, J. Epstein, 2011, Urology.

Longitudinal Assessment of Urinary PCA3 for Predicting Prostate Cancer Grade Reclassification in Favorable Risk Men during Active Surveillance

Jonathan I. Epstein, Mufaddal Mamawala, L. Sokoll, 2017, Prostate Cancer and Prostatic Diseases.

Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent

Robert W Veltri, Alan W Partin, Danil V Makarov, 2008, The Prostate.

DNA content in the diagnostic biopsy for benign‐adjacent and cancer‐tissue areas predicts the need for treatment in men with T1c prostate cancer undergoing surveillance in an expectant management programme

A. Partin, J. Epstein, H. Carter, 2010, BJU international.

Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery.

B. Trock, J. Epstein, J. Tosoian, 2016, European urology.

PD50-04 UTILITY OF MULTIPARAMETRIC MRI IN THE RISK STRATIFICATION OF MEN WITH GRADE GROUP 1 PROSTATE CANCER ON ACTIVE SURVEILLANCE

A. Partin, K. Macura, J. Epstein, 2019, Journal of Urology.

Prostatic growth rate determined from MRI data: age-related longitudinal changes.

W. Christens-Barry, E. Metter, A. Partin, 1999, Journal of andrology.

Conditional probability of reclassification in an active surveillance program for prostate cancer.

J. Epstein, H. Carter, M. Mamawala, 2015, The Journal of urology.

A Novel Quantitative Multiplex Tissue Immunoblotting for Biomarkers Predicts a Prostate Cancer Aggressive Phenotype

Hui Zhang, J. Epstein, S. Hewitt, 2015, Cancer Epidemiology, Biomarkers & Prevention.

Evaluation of apparent diffusion coefficient as a predictor of grade reclassification in men on active surveillance for prostate cancer.

K. Macura, J. Epstein, H. Carter, 2020, Urology.

Prostate-specific antigen and all-cause mortality: results from the Baltimore Longitudinal Study On Aging.

James R. Wright, E. Metter, P. Walsh, 2004, Journal of the National Cancer Institute.

Transperineal Prostate Biopsy Improves the Detection of Clinically Significant Prostate Cancer among Men on Active Surveillance.

A. Partin, K. Macura, J. Epstein, 2020, The Journal of urology.

Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer

L. Sokoll, J. Tosoian, E. Schaeffer, 2016, Urology case reports.

MP51-05 RECLASSIFICATION RATES ARE HIGHER AMONG AFRICAN AMERICAN MEN THAN WHITE MEN ON ACTIVE SURVEILLANCE

B. Trock, J. Epstein, E. Schaeffer, 2014 .

Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer.

B. Trock, J. Epstein, H. Carter, 2014, The Journal of urology.

Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.

A. Partin, P. Landis, Zhaoyong Feng, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.

B. Trock, A. Partin, R. Veltri, 2012, Journal of Urology.

Baseline prostate health index risk category and risk category changes during active surveillance predict grade reclassification.

B. Trock, K. Macura, M. Mamawala, 2023, Urologic oncology.

A Novel Quantitative Multiplex Tissue Immunoblotting for Biomarkers Predicts a Prostate Cancer Aggressive Phenotype

Hui Zhang, J. Epstein, S. Hewitt, 2015, Cancer Epidemiology, Biomarkers & Prevention.

Understanding the Role of the Immune System in the Development of Cancer: New Opportunities for Population-Based Research

C. Marsit, K. Overvad, E. Weiderpass, 2015, Cancer Epidemiology, Biomarkers & Prevention.

Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.

A. Partin, A. Billis, P. Landis, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer.

E. Metter, H. Carter, M. Blackman, 2000, The Journal of clinical endocrinology and metabolism.